E-health to manage distress in patients with an implantable cardioverter-defibrillator: primary results of the WEBCARE trial.

Psychosom Med

From the CoRPS-Department of Medical and Clinical Psychology (M.H., J.D., V.R.M.S., KC.v.d.B., S.S.P.), Tilburg University, the Netherlands; Departmentof Clinical Psychology (P.C., L.W.), Vrije University, Amsterdam, the Netherlands; Department of Cardiology (P.H.v.d.V.), Catharina Hospital, Eindhoven, the Netherlands; Department of Cardiology (J.-.P.H.), Onze Lieve Vrouwe Gasthuis Hospital, Amsterdam, the Netherlands; Department of Cardiology (L.B.), Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands; Department of Cardiology (S.S.D.V.), Vlietland Hospital, Schiedam, the Netherlands; Department of Cardiology (M.A.), Amphia Hospital, Breda, the Netherlands; Department of Cardiology (D.A.M.J.T., S.S.P.), Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Psychology (S.S.P.), University of Southern Denmark, Odense, Denmark; and Department of Cardiology (S.S.P.), Odense University Hospital, Odense, Denmark.

Published: October 2014

Unlabelled: The Web-based distress management program for patients with an implantable cardioverter-defibrillator (ICD; WEBCARE) was developed to mitigate distress and enhance health-related quality of life in ICD patients. This study investigated the treatment effectiveness at 3-month follow-up for generic and disease-specific outcome measures.

Methods: Consecutive patients implanted with a first-time ICD from six hospitals in the Netherlands were randomized to either the "WEBCARE" or the "usual care" group. Patients in the WEBCARE group received a 12-week fixed, six-lesson behavioral treatment based on the problem-solving principles of cognitive behavioral therapy.

Results: Two hundred eighty-nine patients (85% response rate) were randomized. The prevalence of anxiety and depression ranged between 11% and 30% and 13% and 21%, respectively. No significant intervention effects were observed for anxiety (β = 0.35; p = .32), depression (β = -0.01; p = .98) or health-related quality of life (Mental Component Scale: β = 0.19; p = .86; Physical Component Scale: β = 0.58; p = .60) at 3 months, with effect sizes (Cohen d) being small (range, 0.06-0.13). There were also no significant group differences as measured with the disease-specific measures device acceptance (β = -0.37; p = .82), shock anxiety (β = 0.21; p = .70), and ICD-related concerns (β = -0.08; p = .90). No differences between treatment completers and noncompleters were observed on any of the measures.

Conclusions: In this Web-based intervention trial, no significant intervention effects on anxiety, depression, health-related quality of life, device acceptance, shock anxiety, or ICD-related concerns were observed. A more patient tailored approach targeting the needs of different subsets of ICD patients may be warranted.

Trial Registration: clinicaltrials.gov. Identifier: NCT00895700.

Download full-text PDF

Source
http://dx.doi.org/10.1097/PSY.0000000000000096DOI Listing

Publication Analysis

Top Keywords

health-related quality
12
quality life
12
patients implantable
8
implantable cardioverter-defibrillator
8
icd patients
8
anxiety depression
8
intervention effects
8
component scale
8
device acceptance
8
shock anxiety
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!